Paper31300518
miRNAs and NAFLD: from pathophysiology to therapy.
Gjorgjieva M and 4 others. Gut, 2019. Cited by 206 papers, by iCite.
Cite this record
ConductScience Library. miRNAs and NAFLD: from pathophysiology to therapy. Papers, record 31300518. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31300518
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| MicroRNAs | Major topic |
| Non-alcoholic Fatty Liver Disease | Major topic |
| Humans |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04861571 | Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD | Background |
Source ClinicalTrials.gov
Cited by147
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 206 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42873313 | miR-142-3p overexpression targets CLTA and impairs clathrin-mediated endocytosis in HLSECs induced by high glucose. | Acta Diabetol | 2026 | https://conductscience.org/library/papers/42873313 | PubMed |
| 42783602 | Altered miRNA Expression Due to Bisphenol A Exposure and Associated Health Implications: A Narrative Review. | J Xenobiot | 2026 | https://conductscience.org/library/papers/42783602 | PubMed |
| 42589269 | MicroRNA-34a Promotes Hepatic Lipid Accumulation Through RXRα Suppression and Is Reversed by 9-cis-Retinoic Acid in Steatotic Hepatocytes. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589269 | PubMed |
| 42350562 | Systematic assessment for potential endogenous normalizers for microRNA analysis in fecal samples. | Sci Rep | 2026 | https://conductscience.org/library/papers/42350562 | PubMed |
| 42197305 | miR-27a Suppresses Mitochondrial Function to Promote Hepatic Steatosis in High-Fat-Diet-Induced Obesity. | Molecules | 2026 | https://conductscience.org/library/papers/42197305 | PubMed |
| 42138207 | Hepatic p38γ exacerbates acetaminophen‑induced acute liver injury via PI3K/Akt‑dependent mechanisms. | Int J Mol Med | 2026 | https://conductscience.org/library/papers/42138207 | PubMed |
| 42072626 | Hair Follicles as Micro-Organs: MicroRNA-Mediated Control of Growth, Cycling, and Fiber Traits. | Biomolecules | 2026 | https://conductscience.org/library/papers/42072626 | PubMed |
| 41621836 | RNA-Based Therapies for Inherited Metabolic Disorders. | J Inherit Metab Dis | 2026 | https://conductscience.org/library/papers/41621836 | PubMed |
| 41609940 | LncRNA TUG1 promotes hepatic lipid accumulation by targeting the miR-29a-3p/SREBP-2/HMGCR axis in MAFLD. | Funct Integr Genomics | 2026 | https://conductscience.org/library/papers/41609940 | PubMed |
| 41466504 | The Therapeutic Effect and Mechanism of Lactobacillus gardneri on Nonalcoholic Fatty Liver Disease. | J Microbiol Biotechnol | 2025 | https://conductscience.org/library/papers/41466504 | PubMed |
| 41456859 | MicroRNA isomiRs reveal novel pathways linked to disease activity and fibrosis in MASLD. | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/41456859 | PubMed |
| 41226441 | miRNAs, lncRNAs, circRNAs and piRNAs in Nonalcoholic Fatty Liver Disease: Past, Present and Future. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41226441 | PubMed |
| 41104870 | Metabolic dysfunction‑associated steatotic liver disease: Pathogenesis, model and treatment (Review). | Int J Mol Med | 2025 | https://conductscience.org/library/papers/41104870 | PubMed |
| 40980810 | MicroRNA-18a-5p regulates hepatic lipid accumulation in response to high-fat diet. | Front Physiol | 2025 | https://conductscience.org/library/papers/40980810 | PubMed |
| 40943552 | MASLD Under the Microscope: How microRNAs and Microbiota Shape Hepatic Metabolic Disease Progression. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40943552 | PubMed |
| 40901588 | Copper and hepatic lipid dysregulation: Mechanisms and implications. | World J Hepatol | 2025 | https://conductscience.org/library/papers/40901588 | PubMed |
| 40862638 | microRNAs Regulate Cellular Magnesium by Tuning Expression of the Plasma Membrane Protein CNNM4. | ACS Chem Biol | 2025 | https://conductscience.org/library/papers/40862638 | PubMed |
| 40720724 | E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p. | Hepatology | 2026 | https://conductscience.org/library/papers/40720724 | PubMed |
| 40682843 | Protective effect of exercise on metabolic dysfunction‑associated fatty liver disease: Potential epigenetic mechanisms (Review). | Int J Mol Med | 2025 | https://conductscience.org/library/papers/40682843 | PubMed |
| 40668532 | The use of circulating miRNAs for the diagnosis, prognosis, and personalized treatment of MASLD. | J Physiol Biochem | 2025 | https://conductscience.org/library/papers/40668532 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31300518
GET https://conductscience.org/api/papers/v1/31300518/cited_by?page=2